Evaluation of efficacy of dose escalation strategy for treatment with sorafenib for hepatocellular carcinoma.
Not Applicable
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000009126
- Lead Sponsor
- Kanazawa Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Brain metastases. 2. Bleeding tendency. 3. Advanced ascites. 4. Hepatic encephalopathy (II or more). 5. Jaundice (serum bilirubin value of 3.0 mg/dL or more). 6. Serum AST or ALT value of more than 200 IU/L. 7. Hemoglobin blood value of less than 8.0 g/dL. 8. Neutrophil count of less than 1000 /microL. 9. Platelet count of less than 50000 /microL. 10. Difficult to control hypertension. 11. During dialysis. 12. Patients who are pregnant, suspected to be pregnant or breastfeeding. 13. Patient with drug allergy. 14. Patient uses other anticancer drugs. 15. Patients who are considered not to be eligible by the investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Compared with the previously reported the TTS and the OS.
- Secondary Outcome Measures
Name Time Method